PMID- 12036383
OWN - NLM
STAT- MEDLINE
DCOM- 20020723
LR  - 20181130
IS  - 1170-7690 (Print)
IS  - 1170-7690 (Linking)
VI  - 20 Suppl 1
DP  - 2002
TI  - Applications of economic models in healthcare: the introduction of pioglitazone 
      in Sweden.
PG  - 43-53
AB  - Type 2 diabetes mellitus (T2DM) is a common disorder that is estimated to affect 
      approximately 100 million people worldwide. Forecasts have suggested a 
      substantial increase in incidence, mainly in Asia, Africa and North America. 
      Thus, an increasing number of people with diabetes-related complications will 
      have to be cared for in the future. This development will be a major health 
      problem for the people affected, as well as a major health economic challenge for 
      many countries. Thiazolidinediones represent a new class of drugs with a novel 
      mechanism of action that addresses the root cause of T2DM. Their mode of action 
      targets the core defect of T2DM, namely, insulin resistance. One of these drugs, 
      pioglitazone, was recently approved by the Swedish authorities. To evaluate the 
      cost effectiveness of this new drug, a published mathematical simulation model 
      was used. This model was adapted to Swedish conditions, and local Swedish unit 
      costs were put into the model. Modelling is necessary when performing economic 
      evaluations in diabetes because of the complexity of the disease and its long 
      time horizon. The cost-effectiveness analyses showed that the cost per life-year 
      gained with pioglitazone combination therapy compared with current treatment 
      ranged from 37,000 Swedish kronor (SEK) to SEK149,000. Although there is no 
      threshold value for cost effectiveness in Sweden, the values presented would 
      normally be regarded as cost effective in the Swedish healthcare system. 
      Modelling studies are a good starting point, but long-term naturalistic studies 
      are needed to establish the cost effectiveness of these new drugs.
FAU - Henriksson, Freddie
AU  - Henriksson F
AD  - Stockholm School of Economics and Stockholm Health Economics Consulting AB, 
      Stockholm, Sweden. Freddie.Henriksson@hhs.se
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazoles)
RN  - 0 (Thiazolidinediones)
RN  - X4OV71U42S (Pioglitazone)
MH  - *Diabetes Mellitus, Type 2/drug therapy/economics/epidemiology
MH  - *Economics, Pharmaceutical
MH  - Health Care Sector/statistics & numerical data/trends
MH  - Humans
MH  - *Hypoglycemic Agents/economics/therapeutic use
MH  - *Models, Economic
MH  - Pioglitazone
MH  - Prevalence
MH  - Sweden/epidemiology
MH  - *Thiazoles/economics/therapeutic use
MH  - *Thiazolidinediones
RF  - 33
EDAT- 2002/05/31 10:00
MHDA- 2002/07/24 10:01
CRDT- 2002/05/31 10:00
PHST- 2002/05/31 10:00 [pubmed]
PHST- 2002/07/24 10:01 [medline]
PHST- 2002/05/31 10:00 [entrez]
AID - 200005 [pii]
AID - 10.2165/00019053-200220001-00005 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 2002;20 Suppl 1:43-53. doi: 10.2165/00019053-200220001-00005.